This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SNUC | |
|---|---|
| Name | SNUC |
| Synonyms | Sinonasal undifferentiated carcinoma |
| Specialty | Otolaryngology, Oncology, Pathology |
SNUC is a rare, highly aggressive neoplasm arising in the sinonasal tract characterized by rapid local invasion and early metastasis. First described in the 1980s, it is distinguished from other sinonasal malignancies by its undifferentiated histology and dismal prognosis. Management typically involves multimodal therapy combining surgery, radiation, and chemotherapy in reference centers.
SNUC is defined as a high-grade, poorly differentiated epithelial malignancy of the nasal cavity and paranasal sinuses, historically separated from entities such as esthesioneuroblastoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, lymphoma, and malignant melanoma (skin) by morphologic and immunohistochemical criteria. Classification systems from organizations such as the World Health Organization and collaborative pathology groups categorize SNUC within sinonasal epithelial tumors and recommend exclusion of other entities like olfactory neuroblastoma and NUT carcinoma through targeted testing. Contemporary frameworks emphasize integration of morphology, immunoprofile, and molecular data to differentiate SNUC from poorly differentiated variants of nasopharyngeal carcinoma, sinonasal undifferentiated neuroendocrine carcinoma, and postradiation sarcomas.
SNUC is uncommon, with incidence estimates derived from tertiary referral series and cancer registries reporting only a few cases per million population; it predominantly affects adults in their fifth to seventh decades with a male predominance reported in many series. Risk factor associations are limited but have been evaluated alongside exposures linked to sinonasal tumors, including occupational contact with wood dust, nickel, chromium, and practices implicated in cohorts such as workers in textile industry and leather tanning; associations with tobacco smoking and human papillomavirus remain inconsistent across studies. Case series from centers in North America, Europe, and Asia underscore geographic referral patterns and emphasize that prior irradiation to the head and neck is a rare predisposing context.
Patients commonly present with progressive unilateral nasal obstruction, epistaxis, facial pain or numbness, proptosis, and visual disturbance—symptoms that prompt evaluation by specialists at institutions like Mayo Clinic, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center. Endoscopic examination often reveals an exophytic, necrotic mass in the nasal cavity or maxillary, ethmoid, sphenoid, or frontal sinuses; biopsy is essential, with diagnosis established by pathologists referencing protocols from societies such as the College of American Pathologists. Diagnostic workup includes endoscopic biopsy, comprehensive head and neck examination, and multidisciplinary tumor board review at centers like Johns Hopkins Hospital or Cleveland Clinic for treatment planning.
Histologically, SNUC shows sheets of pleomorphic, hyperchromatic cells with high mitotic activity and necrosis; immunohistochemistry is used to exclude entities positive for markers such as cytokeratins, neuroendocrine markers, and lineage-specific proteins referenced in guidelines from the American Society of Clinical Oncology. Typical immunoprofiles include diffuse cytokeratin positivity with variable expression of epithelial membrane antigen, while markers for synaptophysin, chromogranin A, and INSM1 help exclude neuroendocrine tumors; negative results for S100 protein, HMB-45, and desmin assist exclusion of melanoma and sarcoma. Recent molecular studies using techniques developed at institutions like The Broad Institute and University of Pennsylvania have identified heterogeneous genetic alterations, including alterations in TP53, EGFR pathway components, and occasional rearrangements involving genes characterized in other aggressive tumors such as NUTM1; however, no pathognomonic fusion or mutation universally defines SNUC.
Cross-sectional imaging with contrast-enhanced computed tomography and magnetic resonance imaging is indispensable for delineating sinonasal tumor extent, bone destruction, and intracranial or orbital invasion, with protocols aligned to recommendations from radiology departments at Massachusetts General Hospital and Stanford Health Care. 18F‑FDG PET–CT is frequently employed for systemic staging and detection of nodal or distant metastases, following workflows used at Royal Marsden Hospital and major cancer centers. Staging uses the TNM staging system as applied to sinonasal malignancies in staging manuals published by the AJCC and UICC, with advanced T category assigned for skull base, orbital, or intracranial extension.
Optimal therapy is multimodal and often coordinated by multidisciplinary teams at comprehensive cancer centers such as MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Princess Margaret Cancer Centre. When resection is feasible, endoscopic endonasal or open craniofacial approaches performed by surgeons trained at institutions like Karolinska University Hospital or University College London Hospitals aim for negative margins, often followed by adjuvant radiotherapy. Concurrent chemoradiation regimens typically use platinum-based agents (cisplatin or carboplatin) and are influenced by protocols tested in trials and practice at EORTC, RTOG, and national oncology groups like NCCN. For unresectable or metastatic disease, systemic therapy options include multiagent chemotherapy and consideration of clinical trials exploring targeted agents and immunotherapy investigated at centers such as Dana-Farber Cancer Institute and MD Anderson.
Prognosis is generally poor compared with other sinonasal malignancies, with reported 5‑year overall survival rates varying widely across series from leading centers due to stage at presentation and treatment intensity; many large published cohorts from M.D. Anderson Cancer Center and Memorial Sloan Kettering Cancer Center document high local recurrence and distant failure rates. Adverse prognostic factors include advanced T stage with skull base or intracranial extension, nodal involvement, positive resection margins, and poor performance status at presentation; these factors have been evaluated in outcome studies from Johns Hopkins Hospital, Stanford University, and national registries. Given rarity and heterogeneity, enrollment in multicenter trials coordinated by groups such as EORTC and national cooperative groups is recommended to improve evidence for therapeutic strategies.
Category:Sinonasal tumors